Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Genmab A/S stock price, quote, forecast and news

GMAB.CO
DK0010272202
565131

Price

1,829.50
Today +/-
-1.81
Today %
-0.74 %
P

Genmab A/S stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Genmab A/S stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Genmab A/S stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Genmab A/S stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Genmab A/S's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Genmab A/S Stock Price History

DateGenmab A/S Price
8/16/20241,829.50 undefined
8/15/20241,843.00 undefined
8/14/20241,819.00 undefined
8/13/20241,806.50 undefined
8/12/20241,821.00 undefined
8/9/20241,805.00 undefined
8/8/20241,826.50 undefined
8/7/20241,829.00 undefined
8/6/20241,798.50 undefined
8/5/20241,775.50 undefined
8/2/20241,916.50 undefined
8/1/20241,967.00 undefined
7/31/20241,955.00 undefined
7/30/20241,946.50 undefined
7/29/20241,945.00 undefined
7/26/20241,924.00 undefined
7/25/20241,923.50 undefined
7/24/20241,904.50 undefined
7/23/20241,910.00 undefined

Genmab A/S Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Genmab A/S, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genmab A/S from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genmab A/S’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Genmab A/S. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Genmab A/S’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Genmab A/S’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genmab A/S’s growth potential.

Genmab A/S Revenue, EBIT and net profit per share

DateGenmab A/S RevenueGenmab A/S EBITGenmab A/S Net Income
2029e44.71 B undefined0 undefined14.63 B undefined
2028e37.42 B undefined17.75 B undefined12.11 B undefined
2027e33.35 B undefined14.27 B undefined10.15 B undefined
2026e28.03 B undefined9.89 B undefined8.17 B undefined
2025e24.01 B undefined7.87 B undefined6.4 B undefined
2024e20.28 B undefined6.02 B undefined5.29 B undefined
202316.47 B undefined5.32 B undefined4.35 B undefined
202214.51 B undefined6.31 B undefined5.45 B undefined
20218.42 B undefined2.95 B undefined2.96 B undefined
202010.11 B undefined6.31 B undefined4.76 B undefined
20195.37 B undefined2.64 B undefined2.17 B undefined
20183.03 B undefined1.38 B undefined1.47 B undefined
20172.37 B undefined1.37 B undefined1.1 B undefined
20161.82 B undefined1.05 B undefined1.19 B undefined
20151.13 B undefined730.38 M undefined763.51 M undefined
2014850.39 M undefined265.18 M undefined301.3 M undefined
2013663.6 M undefined69.3 M undefined112.4 M undefined
2012484.6 M undefined-116.7 M undefined-487.1 M undefined
2011350.9 M undefined-248.8 M undefined-596.4 M undefined
2010582.1 M undefined-153.3 M undefined-321.5 M undefined
2009586.1 M undefined-498 M undefined-1.01 B undefined
2008745.1 M undefined-870 M undefined-965.1 M undefined
2007529.5 M undefined-437.1 M undefined-383.4 M undefined
2006135.5 M undefined-472.2 M undefined-438.2 M undefined
200598.5 M undefined-427.9 M undefined-393.6 M undefined
20044.1 M undefined-441.3 M undefined-415.2 M undefined

Genmab A/S Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000.0700.10.140.530.750.590.580.350.480.660.851.131.822.373.035.3710.118.4214.5116.4720.2824.0128.0333.3537.4244.71
------94.122,350.0037.76291.8540.83-21.34-0.68-39.8638.2936.9828.2133.2960.2830.2327.9177.3988.43-16.7572.3313.5723.1018.4116.7418.9712.2119.46
---------93.42------------100.00100.0098.63------
0000000000.70000000000008.4214.5116.25000000
-0.02-0.08-0.25-0.48-0.34-0.44-0.43-0.47-0.44-0.87-0.5-0.15-0.25-0.120.070.270.731.051.371.382.646.312.956.315.326.027.879.8914.2717.750
-----502.94-11,025.00-435.71-349.63-82.61-116.78-84.98-26.29-70.86-23.9710.4131.1864.4357.9357.7645.6249.1662.4435.0843.4732.3029.6732.7835.2642.7747.44-
-0.02-0.04-0.17-0.48-0.33-0.42-0.39-0.44-0.38-0.97-1.01-0.32-0.6-0.490.110.30.761.191.11.472.174.762.965.454.355.296.48.1710.1512.1114.63
-111.76366.67185.12-31.7326.91-5.3011.45-12.56151.964.66-68.2285.67-18.29-123.00168.75153.4955.57-7.0833.4547.15119.67-37.8584.38-20.1821.6520.9127.5924.3319.3020.77
5.513.921.822.322.826.531.338.943.944.644.944.944.94651.956.3258.5261.7762.0962.0563.6465.8966.0566.0165.91000000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Genmab A/S Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Genmab A/S is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.041.771.61.371.041.161.251.723.691.761.281.651.11.51.562.663.493.925.426.1110.9716.0819.3422.3228.14
00000000000000.140.140.110.170.980.581.332.992.463.375.714.95
00000000000000000057.6900249311820
00000000034.60000000000000057
0.81.65.822.29.616.15.67.48.7767704.7355.213.400000000000
0.041.771.611.371.041.171.271.733.71.812.042.351.461.651.692.773.674.96.067.4313.9618.7922.7428.2233.14
000.050.090.070.060.040.030.040.980.060.040.030.030.020.030.030.030.110.160.410.740.981.321.64
00.020.020.010.010.01000000000000000.151.080.370.130.13
000006000007.29.89.46.26.436.861.478.769.621120274862
41.912799.464.633.810.7000000002.562.53192.64181.9124.4470.36470338254146101
000000000313.8000000000000000
00034.600000-0.24.613.35.43.77.25.696.34125.04296.95386.45139177264252212
0.040.150.170.20.110.080.050.030.041.290.070.060.050.040.040.10.230.340.541.031.182.351.891.92.15
0.081.921.771.571.151.251.321.763.743.12.112.421.51.691.732.873.95.246.68.4615.1421.1424.6330.1235.29
0.721.821.822.72329.833.139.644.544.944.944.944.950.351.856.9759.5360.3561.1961.56566666666
0.11.921.932.072.092.592.93.785.345.375.385.385.385.735.896.927.567.777.988.0611.7611.8912.0312.3112.46
-0.02-0.07-0.24-0.7-1.02-1.44-1.81-2.21-2.5-3.23-4.12-4.34-4.93-5.4-5.28-5.03-4.23-3-1.85-0.22.137.1110.0214.8119.02
000000000000000094.48082.0891.719854819860
0000000000000000000000000
0.081.871.711.41.091.181.121.612.882.191.31.080.490.380.661.953.494.836.278.0114.0519.1222.227.2831.61
2.113.828.394.62415.814.547.476.99144.832.833.5000000000350245330
000000000087.100000000000296481637
00.010.030.050.030.050.210.130.980.960.761.290.941.180.910.660.410.410.330.440.911.210.861.021.43
0000000000000000000000000
015.216.216.817.188.677.55.776.15.83.82.100.120002642627490
00.040.070.160.080.070.240.191.071.060.891.320.981.180.910.660.410.410.330.440.941.251.571.822.48
040.829.923.618.62114.511.38.2917.911.86.11.90.40.120000155277363523680
0000000000000000000000000
0000000004.712.165.195.2124.2164.1177.661.4303.633.293492500491515
00.040.030.020.020.020.010.010.010.010.030.080.10.130.160.1800000.160.770.861.011.2
00.080.10.180.090.090.250.21.081.070.921.41.081.311.070.830.420.410.330.451.12.022.432.843.68
0.081.951.811.581.181.271.371.83.963.262.222.481.561.691.732.783.95.246.68.4615.1421.1424.6330.1235.29
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Genmab A/S provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Genmab A/S's financial health and stability.

Assets

Genmab A/S's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Genmab A/S must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Genmab A/S after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Genmab A/S's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0.02-0.08-0.25-0.53-0.34-0.44-0.39-0.44-0.38-0.96-0.34-0.12-0.21-0.110.070.30.761.131.061.612.865.93.987.045.64
719344763533117148583211515111231406987139259248362295
0000000000000000000000000
00.050.080.12-0.020.020.160.040.840.12-0.040.37-0.180.2-0.21-0.17-0.49-0.820.1-0.54-1.6-0.34-1.32-3.251.18
0113470-1-10437250-2733-57-304-49-24356-140-69609-687-239270
000000000000000000202020121625
00000000000.010.030.01-00-0-0.01-0.010.18-0.050.481.480.741.581.07
-0.01-0.01-0.12-0.31-0.3-0.37-0.21-0.380.51-0.51-0.570.27-0.440.07-0.130.130.310.331.591.011.336.432.233.917.38
0-4-36-58-14-8-2-1-13-53-16-10-7-9-10-75-135-33-88-477-111-307-252-317-376
0-1,768250238361-25-127-451-2,362460974-738514-41667-1,010-480-1,014-667-1,777-1,983-2,351-961-2,761-1,282
0-1,763286297376-16-125-449-2,349513991-728522-40777-935-345-981-579-1,300-1,872-2,044-709-2,444-906
0000000000000000000000000
0000-4-6-9-9-7-8-8-7-6-6-3-30000-31-44-58-73-91
000000.060.050.090.040.030000.370.161.060.640.090.21-0.073.940.14-0.31-0.63-0.41
0.051.7800.16-00.50.30.881.560.03-0.01-0.01-0.010.360.151.040.640.090.21-0.073.660.07-0.42-0.79-0.61
0.051.7700.1600.450.260.81.530000-0000000-0.25-0.03-0.05-0.09-0.1
0000000000000000000000000
0.0400.130.090.060.11-0.040.05-0.3-0.060.39-0.470.070.010.090.190.51-0.571.04-0.813.023.711.70.944.97
-10.1-13.2-159.3-367.2-317.1-376-211-381.5492.6-566.3-586.9258.1-444.461.9-138.457.23176.06294.611,500.46537.421,2156,1261,9763,5957,004
0000000000000000000000000

Genmab A/S stock margins

The Genmab A/S margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genmab A/S. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genmab A/S.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Genmab A/S's sales revenue. A higher gross margin percentage indicates that the Genmab A/S retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Genmab A/S's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Genmab A/S's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genmab A/S's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genmab A/S. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genmab A/S's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Genmab A/S Margin History

Genmab A/S Gross marginGenmab A/S Profit marginGenmab A/S EBIT marginGenmab A/S Profit margin
2029e98.63 %0 %32.73 %
2028e98.63 %47.44 %32.37 %
2027e98.63 %42.77 %30.45 %
2026e98.63 %35.26 %29.13 %
2025e98.63 %32.78 %26.66 %
2024e98.63 %29.67 %26.11 %
202398.63 %32.3 %26.42 %
2022100 %43.47 %37.59 %
2021100 %35.08 %35.13 %
202098.63 %62.44 %47.06 %
201998.63 %49.16 %40.37 %
201898.63 %45.63 %48.66 %
201798.63 %57.76 %46.65 %
201698.63 %57.97 %65.36 %
201598.63 %64.46 %67.39 %
201498.63 %31.18 %35.43 %
201398.63 %10.44 %16.94 %
201298.63 %-24.08 %-100.52 %
201198.63 %-70.9 %-169.96 %
201098.63 %-26.34 %-55.23 %
200998.63 %-84.97 %-172.46 %
200893.45 %-116.76 %-129.53 %
200798.63 %-82.55 %-72.41 %
200698.63 %-348.49 %-323.39 %
200598.63 %-434.42 %-399.59 %
200498.63 %-10,763.42 %-10,126.83 %

Genmab A/S Stock Sales Revenue, EBIT, Earnings per Share

The Genmab A/S earnings per share therefore indicates how much revenue Genmab A/S has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genmab A/S earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genmab A/S's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genmab A/S’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genmab A/S's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genmab A/S Revenue, EBIT and net profit per share

DateGenmab A/S Sales per ShareGenmab A/S EBIT per shareGenmab A/S Earnings per Share
2029e704.39 undefined0 undefined230.52 undefined
2028e589.67 undefined0 undefined190.89 undefined
2027e525.53 undefined0 undefined160.01 undefined
2026e441.72 undefined0 undefined128.69 undefined
2025e378.38 undefined0 undefined100.86 undefined
2024e319.54 undefined0 undefined83.42 undefined
2023249.93 undefined80.73 undefined66.02 undefined
2022219.74 undefined95.52 undefined82.59 undefined
2021127.44 undefined44.71 undefined44.77 undefined
2020153.46 undefined95.82 undefined72.22 undefined
201984.32 undefined41.45 undefined34.04 undefined
201848.76 undefined22.25 undefined23.73 undefined
201738.09 undefined22.01 undefined17.77 undefined
201629.4 undefined17.05 undefined19.22 undefined
201519.36 undefined12.48 undefined13.05 undefined
201415.1 undefined4.71 undefined5.35 undefined
201312.79 undefined1.34 undefined2.17 undefined
201210.53 undefined-2.54 undefined-10.59 undefined
20117.82 undefined-5.54 undefined-13.28 undefined
201012.96 undefined-3.41 undefined-7.16 undefined
200913.05 undefined-11.09 undefined-22.51 undefined
200816.71 undefined-19.51 undefined-21.64 undefined
200712.06 undefined-9.96 undefined-8.73 undefined
20063.48 undefined-12.14 undefined-11.26 undefined
20053.15 undefined-13.67 undefined-12.58 undefined
20040.15 undefined-16.65 undefined-15.67 undefined

Genmab A/S business model

Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.com.

Genmab A/S SWOT Analysis

Strengths

Genmab A/S has a strong portfolio of innovative and differentiated biopharmaceutical products.

The company has a robust research and development pipeline with potential for future growth and revenue generation.

Genmab A/S has established strategic partnerships with leading pharmaceutical companies, enhancing its market presence and expanding commercial opportunities.

Weaknesses

The company's dependency on a limited number of products makes it susceptible to fluctuations in the market and competitive pressures.

Genmab A/S may face challenges in terms of regulatory approvals, as the biopharmaceutical industry is highly regulated.

The high costs associated with research and development activities may strain the company's financial resources.

Opportunities

The growing demand for innovative biopharmaceutical products presents significant growth opportunities for Genmab A/S.

Strategic partnerships and collaborations can help the company expand its product portfolio and explore new markets.

Advancements in technology and scientific discoveries provide potential for the development of breakthrough therapies.

Threats

Intense competition within the biopharmaceutical industry may adversely affect Genmab A/S' market share and profitability.

Delayed or unsuccessful clinical trials can impact the company's ability to bring products to market.

Changes in healthcare policies and regulations can pose challenges to pricing and reimbursement of Genmab A/S' products.

Genmab A/S Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Genmab A/S historical P/E ratio, EBIT, and P/S ratio.

Genmab A/S shares outstanding

The number of shares was Genmab A/S in 2023 — This indicates how many shares 65.915 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genmab A/S earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genmab A/S's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genmab A/S’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genmab A/S's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Genmab A/S.

Genmab A/S latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202420.98 1.5  (-92.83 %)2024 Q2
3/31/202412.07 20.18  (67.24 %)2024 Q1
12/31/202323.41 9.67  (-58.69 %)2023 Q4
9/30/202320.89 32.32  (54.68 %)2023 Q3
6/30/202319.99 20.61  (3.11 %)2023 Q2
3/31/20235.45 3.43  (-37.05 %)2023 Q1
12/31/202226.62 8.77  (-67.05 %)2022 Q4
9/30/202219.01 39.17  (106.07 %)2022 Q3
6/30/202214.37 28.66  (99.44 %)2022 Q2
3/31/20225.6 7.05  (25.92 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Genmab A/S stock

Eulerpool World ESG Rating (EESG©)

91/ 100

🌱 Environment

86

👫 Social

99

🏛️ Governance

88

Environment

Scope 1 - Direct Emissions
283.1
Scope 2 - Indirect emissions from purchased energy
110.7
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
393.8
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees58
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Genmab A/S list of shareholders

%
Name
Stocks
Change
Date
7.08 % BlackRock Institutional Trust Company, N.A.4,493,0687,68112/31/2023
5.30 % Baillie Gifford & Co.3,363,182-11,4752/29/2024
5.10 % Wellington Management Company, LLP3,237,113-59,65412/29/2023
3.02 % The Vanguard Group, Inc.1,915,6084,2313/31/2024
2.54 % Norges Bank Investment Management (NBIM)1,610,526-59,10712/31/2023
1.78 % Capital Research Global Investors1,127,943307,4623/31/2024
1.53 % Amundi Asset Management, SAS968,372207,8923/31/2024
1.16 % Handelsbanken Kapitalförvaltning AB738,51742,4803/31/2024
1.15 % Harding Loevner LP727,69203/31/2024
0.96 % BlackRock Advisors (UK) Limited609,3341093/31/2024
1
2
3
4
5
...
10

Genmab A/S Executives and Management Board

Dr. Jan Van De Winkel62
Genmab A/S President, Chief Executive Officer
Compensation 44.3 M
Mr. Anthony Mancini53
Genmab A/S Chief Operating Officer, Executive Vice President
Compensation 21.8 M
Dr. Judith Klimovsky67
Genmab A/S Executive Vice President, Chief Development Officer
Compensation 21.7 M
Dr. Tahamtan Ahmadi51
Genmab A/S Executive Vice President, Chief Medical Officer, Head of Experimental Medicines (since 2021)
Compensation 19.8 M
Mr. Anthony Pagano46
Genmab A/S Chief Financial Officer, Executive Vice President (since 2020)
Compensation 19.6 M
1
2
3
4

Genmab A/S Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
CureVac Stock
CureVac
SupplierCustomer0,820,120,230,530,78-
H Lundbeck Stock
H Lundbeck
SupplierCustomer0,780,160,100,310,72-0,20
Amgen Stock
Amgen
SupplierCustomer0,52-0,800,470,04-0,31-0,40
Seagen Stock
Seagen
SupplierCustomer0,43-0,180,380,650,780,25
Immatics Stock
Immatics
SupplierCustomer0,370,890,850,540,780,49
BioNTech ADR Stock
BioNTech ADR
SupplierCustomer0,35-0,550,310,530,780,75
Bolt Biotherapeutics Stock
Bolt Biotherapeutics
SupplierCustomer0,29-0,120,290,81-
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,13-0,400,34-0,14-0,40-0,04
ADC Therapeutics Stock
ADC Therapeutics
SupplierCustomer-0,070,950,530,470,84-0,03
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals
SupplierCustomer-0,200,830,480,540,460,23
1
2

Most common questions regarding Genmab A/S

What values and corporate philosophy does Genmab A/S represent?

Genmab A/S represents values of innovation, dedication, and patient focus. The company believes in developing innovative antibody treatments to improve the lives of patients suffering from cancer and other diseases. Genmab prioritizes scientific excellence, collaboration, and striving for the best patient outcomes. Their corporate philosophy revolves around pushing boundaries, challenging the status quo, and making a meaningful impact in the field of biotechnology. Genmab A/S aims to deliver outstanding value for patients, healthcare providers, and shareholders through their commitment to research, development, and commercialization of novel antibody-based therapies.

In which countries and regions is Genmab A/S primarily present?

Genmab A/S, a leading biotechnology company, is primarily present in various countries and regions. As a globally recognized player in the pharmaceutical industry, Genmab A/S has an extensive presence. The company operates in key markets such as the United States, Europe, Asia, and the Middle East. With a strong international footprint, Genmab A/S actively engages in research, development, and commercialization of innovative antibody-based therapies. Its continued growth and success are fueled by collaborations, partnerships, and a commitment to advancing breakthrough treatments for patients worldwide.

What significant milestones has the company Genmab A/S achieved?

Genmab A/S, a leading biotechnology company, has achieved several significant milestones. One of the notable accomplishments is the development and approval of Darzalex (daratumumab), a breakthrough therapy for multiple myeloma. Genmab also entered into groundbreaking collaborations with renowned pharmaceutical companies, securing licensing agreements for their proprietary technology platforms. Additionally, the company has garnered worldwide recognition for its robust pipeline of innovative antibody-based therapies, addressing various unmet medical needs. Furthermore, Genmab's commitment to scientific excellence and steadfast dedication to improving patients' lives have earned them numerous prestigious awards and accolades within the biopharmaceutical industry.

What is the history and background of the company Genmab A/S?

Genmab A/S is a Danish biotechnology company founded in 1999. The company specializes in the development of antibody therapeutics for the treatment of cancer and other diseases. Genmab has a strong focus on innovation and leveraging its proprietary antibody technologies to create novel drugs. Over the years, Genmab has established strategic collaborations with several pharmaceutical companies to advance its drug candidates. Notably, Genmab achieved significant success with the launch of Darzalex, an antibody-based therapy approved for multiple myeloma. The company continues to explore and develop groundbreaking therapies, harnessing the power of antibodies to improve patient outcomes and quality of life.

Who are the main competitors of Genmab A/S in the market?

The main competitors of Genmab A/S in the market include global pharmaceutical companies such as Roche Holding AG, Johnson & Johnson, Bristol-Myers Squibb Company, and Novartis AG. These companies are prominent players in the biopharmaceutical industry, engaging in research, development, and commercialization of innovative therapies. With its focus on the development of antibody-based drugs to treat cancer and other diseases, Genmab faces stiff competition in this highly regulated and competitive market. However, Genmab has established a strong reputation and is well-positioned with its innovative pipeline and strategic collaborations in the industry.

In which industries is Genmab A/S primarily active?

Genmab A/S is primarily active in the biotechnology industry.

What is the business model of Genmab A/S?

The business model of Genmab A/S, a Danish biotechnology company, focuses on the development and commercialization of novel antibody therapeutics for the treatment of cancer. Genmab A/S specializes in the creation of differentiated and innovative antibody products, which are based on its proprietary antibody technologies. The company collaborates with various partners to advance its products through preclinical and clinical development stages. Genmab A/S aims to meet the needs of patients by discovering and delivering breakthrough treatments that target specific antigens involved in the progression of different types of cancer.

What is the P/E ratio of Genmab A/S 2024?

The Genmab A/S P/E ratio is 22.78.

What is the P/S ratio of Genmab A/S 2024?

The Genmab A/S P/S ratio is 5.95.

What is the AlleAktien quality score of Genmab A/S?

The AlleAktien quality score for Genmab A/S is 7/10.

What is the revenue of Genmab A/S 2024?

The expected Genmab A/S revenue is 20.28 B DKK.

How high is the profit of Genmab A/S 2024?

The expected Genmab A/S profit is 5.29 B DKK.

What is the business model of Genmab A/S

Genmab A/S is an internationally leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer. The company, founded in 1999, is headquartered in Copenhagen, Denmark. Genmab also has offices in the United States, the Netherlands, Luxembourg, Japan, and China. Genmab operates its business in two main divisions: Research and Development, and Commercialization and Sales. Genmab's Research and Development department focuses on the discovery, development, and testing of antibodies for the treatment of cancer. The company is dedicated to developing innovative therapies for various types of cancer, including blood cancer, solid tumors, and hematological malignancies. Genmab's flagship product is Darzalex® (daratumumab), a monoclonal antibody for the treatment of patients with multiple myeloma. Darzalex® is now approved in the United States and distributed worldwide. Genmab also has a range of other antibodies in various stages of development, including tisotumab vedotin for the treatment of cervical cancer and advanced urothelial cancer, and enapotamab vedotin for the treatment of patients with solid tumors. The company works closely with other pharmaceutical and biotech companies to advance its research and development activities. Genmab has partnerships with companies such as Janssen Biotech, Novartis Pharmaceuticals, and Seattle Genetics to jointly develop and commercialize innovative therapies. Genmab's Commercialization and Sales department is responsible for the marketing and distribution of Darzalex® and other products. The company collaborates with other pharmaceutical companies, distribution partners, and regulatory authorities to ensure that the products are available, approved in the relevant markets, and accessible to patients. Genmab's business model is based on the development and commercialization of innovative and effective cancer therapies that meet the needs of patients. The company is committed to investing continuously in research and development and expanding its product pipeline to bring more therapies to the market in the future. Additionally, Genmab works closely with other companies to expand its reach and activities and further strengthen the company. In summary, Genmab A/S is an innovative biopharmaceutical company specializing in the development and commercialization of cancer therapies. The company has a wide range of products and a strong presence in the global market. With a strong research and development department and a dedicated sales department, Genmab aims to continue expanding and developing innovative therapies to meet the needs of patients.

What is the Genmab A/S dividend?

Genmab A/S pays a dividend of 0 DKK distributed over payouts per year.

How often does Genmab A/S pay dividends?

The dividend cannot currently be calculated for Genmab A/S or the company does not pay out a dividend.

What is the Genmab A/S ISIN?

The ISIN of Genmab A/S is DK0010272202.

What is the Genmab A/S WKN?

The WKN of Genmab A/S is 565131.

What is the Genmab A/S ticker?

The ticker of Genmab A/S is GMAB.CO.

How much dividend does Genmab A/S pay?

Over the past 12 months, Genmab A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genmab A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Genmab A/S?

The current dividend yield of Genmab A/S is .

When does Genmab A/S pay dividends?

Genmab A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genmab A/S?

Genmab A/S paid dividends every year for the past 0 years.

What is the dividend of Genmab A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genmab A/S located?

Genmab A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genmab A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genmab A/S from 8/21/2024 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 8/21/2024.

When did Genmab A/S pay the last dividend?

The last dividend was paid out on 8/21/2024.

What was the dividend of Genmab A/S in the year 2023?

In the year 2023, Genmab A/S distributed 0 DKK as dividends.

In which currency does Genmab A/S pay out the dividend?

The dividends of Genmab A/S are distributed in DKK.

All fundamentals about Genmab A/S

Our stock analysis for Genmab A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genmab A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.